Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has announced the launch of "Favijaj" (Favipiravir) an antiviral drug used for treating patients suffering from influenza virus and has proved to be effective over COVID patients. BHL has received approval from India's drug regulator, to manufacture and market "Favijaj" the oral Favipiravir approved medication in India for the treatment of COVID-19 from 4th May 2021.
"FAVIJAJ" tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate Covid-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus.
Commenting on the launch of "Favijaj" (Favipiravir), Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to add Favipiravir to our growing product portfolios. The second waves is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure, and offer patients much needed and timely therapy option."
BHL has successfully developed the active pharmaceutical ingredient (API) and the formulation for Favipiravir through its own in-house R&D team. Most patients ailing from mild to moderate symptoms can benefit from the use of Favijaj. The drug will be available as a prescription-based medication, with recommended doses.
The drug controller of India's has granted permissions to supply the "Favijaj" (Favipiravir) in the domestic as well as in overseas market.
Shares of Bajaj Healthcare Ltd was last trading in BSE at Rs.526 as compared to the previous close of Rs. 511.55. The total number of shares traded during the day was 81193 in over 1509 trades.
The stock hit an intraday high of Rs. 534.95 and intraday low of 512. The net turnover during the day was Rs. 42878492.